Pfizer Inc PFE

$30.72 +0.72 (2.40%)

Valuation

Market cap
174,808,992,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
10.01
P/E (forward)
10.36
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
31,459,352
Avg volume
32,554,289
Day's range
$30.04 – $30.90
Shares out
5,699,674,000
Stochastic %K
42%
Beta
0.31
Analysts
Hold
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

RookyMoves Nov 4, 7:34 PM
$PFE Stage 1 base breakout around 31. Huge level for bulls. A weekly close above would be very encouraging.
0 replies
Stocktradesmoon Nov 4, 7:24 PM
$ABCL ❤️ $REGN $PFE $MRNA $SLS $ABCL : 4 new Street initiations in 5 weeks 👀 Do people trade price targets? Goldman (Sep 24): Neutral, $13 JPMorgan (Sep 29): Overweight, $17 UBS (Oct 12): Buy, $18 Jefferies (Oct 30): Buy, $21 The big banks are showing up. On the chart I’m watching for a higher low ✅ done!! We about to attempt the $15 breakout. 👀😉 ABcellera 🔥 🔥 👀!!!
0 replies
PredictionFLO1 Nov 4, 6:18 PM
$PFE options flow lesson: one options print is evidence, not a complete thesis. A large print can be directional, hedged, or one leg of a spread. Price structure and the next open interest settle help grade it. The alert snapshot shows $620K in the Nov 6 $30 calls. Volume was 0.6x standing open interest at capture. Intraday volume does not establish whether a position was opened or held; the next settled open interest is the check.
0 replies
Stocktradesmoon Nov 4, 6:03 PM
$ABCL ❤️ $MRNA $REGN $SLS $PFE $ABCL 🧬 13 Dollar Resistance 13 dollars is in sight. But this guy won’t open the door without a fight. 😂 Now what we need isn’t the chart—it’s a reason to break through. 🔥November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. The market’s already seen the Phase 2 topline. This time, it needs to show something more in 12-week durability, sleep, safety, and redosing. The chart brought us right to the door at 13 dollars. The one to kick it down is the data. Alright, 635. Let’s OPEN that door. 🚪💥
0 replies
Stocktradesmoon Nov 4, 5:51 PM
$ABCL $MRNA $REGN $SLS $PFE $ABCL 👀🔥 ABcellera 🔥!!! There is zero fundamental reason to support ABCL falling in price. If anything, the stock is too cheap right now. People don’t understand the sheer magnitude of what this company will do, and sadly those people will be left behind… I’m just sitting back with a boatload of shares waiting for the actual breakout to happen. We’ve seen nothing yet, IMO! Don’t get me wrong, I welcome sales in the market and will just keep buying but I don’t think we go anywhere but up…
0 replies
Stocktradesmoon Nov 4, 5:45 PM
$ABCL $MRNA $PFE $REGN $SLS Money starting to Roll in as expected….ONLY THE BEGINNING!!!! $28 million upfront payment to AbCellera 🤑🤑🤑💰💰💰💰💵💵💵💵💵💵💸💸
0 replies
jrh34 Nov 4, 5:23 PM
$PFE This is the stock to own for 2027.
0 replies
Stocktradesmoon Nov 4, 5:22 PM 0 replies